amgen maritide - Search News

Amgen Inc. Q4 Profit Decreases

Amgen profit beats estimates, next MariTide studies start by mid-year

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.

Business Insider · 12h

Amgen Inc. Q4 Profit Decreases, But Beats Estimates

Amgen Inc. (AMGN) reported a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.

Houston Chronicle · 12h

Amgen: Q4 Earnings Snapshot

The average estimate of 13 analysts surveyed by Zacks Investment Research was for earnings of $5.03 per share. The world's largest biotech drugmaker posted revenue of $9.09 billion in the period, also beating Street forecasts.

FDA, Amgen and obesity

FierceBiotech · 11h

Amgen’s early-stage obesity asset slapped with FDA hold

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial

STAT · 11h

Study of Amgen’s early obesity candidate paused by FDA

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to reopen the study.

Business Insider · 12h

Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with

10hon MSN

Amgen profits rise, next MariTide studies start by mid-year

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

The Motley Fool: An inside look at Amgen’s fall

Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...

Amgen Inc (AMGN) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

The Motley Fool: Not-so-bad cinical trial results

Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a ...

pharmaphorum5d

Amgen's big reveal of obesity data falls a little flat

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

12h

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

ENDPOINTS NEWS8h

Amgen announces hold on Ph1 obesity candidate, pipeline cuts

Amgen's obesity drug AMG-513 on clinical hold; company reaffirms obesity market ambitions while advancing MariTide program ...

1don MSN

Amgen's SWOT analysis: stock outlook amid obesity drug race

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results